Regeneron Presents P-III Trial Results of Dupixent (dupilumab) for Eosinophilic Esophagitis in Children Aged 1 to 11 Years at UEG 2022
Shots:
- The P-III trial evaluating Dupixent (SC, high/low dose regimen) vs PBO in young children aged 1-11yrs. with EoE
- The results showed that 68% in high dose & 58% in low dose achieved histological disease remission vs 3% @16wk., improvements in abnormal endoscopic findings of their esophagus in children with the higher dose regimen with a reduction of 3.5 vs 0.3 points, improvement in the proportion of days children experienced disease symptoms but not significant
- In a prespecified exploratory analysis, a high dose led to a 3.09% vs 0.29% increase in body weight, safety results were consistent with the known safety profile of Dupixent in its approved EoE, AEs rate (79% vs 91%), AEs leads to treatment discontinuation before 16wk. (0% vs 6%)
Ref: PRNewswire | Image: Regeneron
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
